The Pathological Microenvironment and Smart Nanotherapies for Diabetes-Associated Erectile Dysfunction: From Redox Regulation to Neurovascular Remodeling
Pharmaceutics · 10.11.2026 · 18 (11) · 1455
DOI: 10.3390/pharmaceutics18111455 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 10.11.2026. Verfasst von Tang Tang und 5 weiteren Autor:innen. Die Arbeit nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chengdu Medical Research Project.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetes mellitus-associated erectile dysfunction (DMED) is characterized by impaired nitric oxide signaling, microvascular injury, neuropathy, metabolic dysfunction, and cavernosal remodeling. These abnormalities may limit responses to phosphodiesterase type 5 inhibitors and compromise regenerative treatment. This focused narrative review examines the potential of nanotherapeutic delivery and microenvironment modulation to address these pathological barriers. We discuss catalytic nanozymes, hypoxia/reactive oxygen species-responsive neurotrophic constructs, mitochondria-targeted piezoelectric systems, fructose-1,6-bisphosphatase 1 (FBP1) mRNA-loaded lipid nanoparticles, and extracellular vesicle–hydrogel composites. By distinguishing cell experiments, interventions in diabetic animals, human observational studies, and early clinical experience with related non-nanoparticle interventions, we compare representative platforms in terms of mechanism, administration route, functional endpoints, biodistribution, duration of effect, and safety. Human functional studies provide strong evidence for impaired nitric oxide signaling, whereas therapeutic strategies targeting lactate metabolism, lactylation, ferroptosis, and mitochondrial turnover remain predominantly at the preclinical stage. We further discuss the potential value of candidate clinical phenotypes and exploratory biomarkers for future patient stratification and examine key translational challenges, including local dosing feasibility, off-target exposure, repeated-dose immunogenicity, reproductive safety, and manufacturing consistency. Overall, current findings provide a mechanistic rationale and research direction for further development of DMED nanotherapies. Further preclinical validation and clinical studies are needed to establish their efficacy, safety, and potential advantages over standard treatment.
Förderung
- National Natural Science Foundation of China
- Chengdu Medical Research Project
Zitieren
APA
Tang, T., Zhao, Y., Zhang, T., Ma, J., Ma, Z., & Zhang, P. (2026). The Pathological Microenvironment and Smart Nanotherapies for Diabetes-Associated Erectile Dysfunction: From Redox Regulation to Neurovascular Remodeling. Pharmaceutics, 18(11), 1455. https://doi.org/10.3390/pharmaceutics18111455
Vancouver
Tang T, Zhao Y, Zhang T, Ma J, Ma Z, Zhang P. The Pathological Microenvironment and Smart Nanotherapies for Diabetes-Associated Erectile Dysfunction: From Redox Regulation to Neurovascular Remodeling. Pharmaceutics. 2026;18(11):1455. doi:10.3390/pharmaceutics18111455
BibTeX
@article{Tang2026,
author = {Tang, Tang and Zhao, Yipeng and Zhang, Tao and Ma, Jian and Ma, Ziyang and Zhang, Peihai},
title = {The Pathological Microenvironment and Smart Nanotherapies for Diabetes-Associated Erectile Dysfunction: From Redox Regulation to Neurovascular Remodeling},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1455},
doi = {10.3390/pharmaceutics18111455}
}
EUVIMED